Anti-cancer effect of bix01294 towards CML cell lines / Loh Sheng Wei

Loh , Sheng Wei (2017) Anti-cancer effect of bix01294 towards CML cell lines / Loh Sheng Wei. Masters thesis, University of Malaya.

[img] PDF (Dissertation (M.A)
Restricted to Repository staff only until 31 December 2019.

Download (3919Kb)

    Abstract

    Background: H3K9 methylation is one of the essential histone post-translational modifications for heterochromatin formation and transcriptional repression. Recently, several studies have demonstrated that H3K9 methylation negatively regulates the type I interferon response. Results: I report the application of EHMT1 and EHMT2 specific chemical inhibitors to sensitize CML cell lines to interferon and imatinib treatments. Inhibition of EHMT1 and EHMT2 with BIX01294 enhances the cytotoxicity of IFNα2a in four CML cell lines, K562, KCL22, BV173 and KT1. Chromatin immunoprecipitation assay shows that BIX01294 treatment enhances type I interferon response by reducing H3K9me2 at the promoters of interferon-stimulated genes. Additionally, BIX01294 treatment augments IFNα2a- and imatinib-mediated apoptosis in CML cell lines. Moreover, my data suggest that the expression level of EHMT1 and EHMT2 inversely correlates with the type I interferon responsiveness in CML cell lines. Conclusions: My study sheds light on the role of EHMT1 and EHMT2 as potential targets in improving the efficacy of standard treatments of CML.

    Item Type: Thesis (Masters)
    Additional Information: Dissertation (M.A.) – Faculty of Science, University of Malaya, 2019. MST
    Uncontrolled Keywords: Anti-cancer; Cell treatment; Standard treatments
    Subjects: Q Science > Q Science (General)
    R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
    Divisions: Faculty of Science
    Depositing User: Mr Mohd Safri Tahir
    Date Deposited: 23 Mar 2017 11:56
    Last Modified: 23 Mar 2017 11:56
    URI: http://studentsrepo.um.edu.my/id/eprint/7251

    Actions (For repository staff only : Login required)

    View Item